Earnings History Data for Emergent BioSolutions Inc. (EBS) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
06-11-2024	AH		EBS	Emergent BioSolutions Inc.	463.99	1.37	0.49	-1.44	Emergent Biosolutions GAAP EPS of $1.37 beats by $1.68, revenue of $293.8M misses by $3.7M [11/6/2024 4:43 PM]	11.11	1.91 (20.71%)	11.39	2.19 (23.80%)	1.42 - 15.10	5,154,675	1,030,000	150,339
Emergent Biosolutions non-GAAP EPS of $1.37 beats by $1.23, revenue of $293.8M misses by $3.7M [11/6/2024 4:43 PM] Emergent Biosolutions stock jumps 14% post-market on guidance raise [11/6/2024 6:13 PM] Emergent BioSolutions Reports Third Quarter 2024 Financial Results [2024-11-06 04:05PM] Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript [2024-11-07 01:15AM] Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates [Nov-06-24 06:20PM] Emergent Biosolutions: Q3 Earnings Snapshot [Nov-06-24 05:17PM] Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa [Nov-06-24 04:49PM]
06-08-2024	PM		EBS	Emergent Biosolutions, Inc.	553.89	-2.32	-0.97	-1.06	Emergent BioSolutions Non-GAAP EPS of -$2.32 misses by $1.35, revenue of $254.7M beats by $64.7M [8/7/2024 12:36 AM]	5.72	-4.13 (-41.94%)	6.36	-3.50 (-35.50%)	1.42 - 15.10	6,757,596	2,600,000	172,245
Emergent BioSolutions plunges 37% on Q2 EPS miss, wider projected 2024 net loss [8/6/2024 7:40 PM] Emergent BioSolutions Non-GAAP EPS of -$2.32 misses by $1.35, revenue of $254.7M beats by $64.7M [8/7/2024 12:36 AM]
01-05-2024	AH		EBS	Emergent Biosolutions, Inc.	98.66	0.59	0.00	-3.17	Emergent Biosolutions Non-GAAP EPS of $0.59 beats by $1.45, revenue of $300.4M beats by $75.9M [5/1/2024 5:03 PM]	3.29	1.36 (70.73%)	2.89	0.96 (49.74%)	1.42 - 10.88	141,170,576	1,190,000	9,081,980
Emergent BioSolutions gains as results top estimates, co to cut 300 jobs [5/2/2024 5:22 AM] Emergent Biosolutions Non-GAAP EPS of $0.59 beats by $1.45, revenue of $300.4M beats by $75.9M [5/1/2024 5:03 PM] Emergent BioSolutions announces reduction of about 300 employees [5/1/2024 4:24 PM]
06-03-2024	AH		EBS	Emergent Biosolutions, Inc.	171.22	-0.77	-0.33	-0.31	Emergent Biosolutions Non-GAAP EPS of -$0.77 misses by $0.45, revenue of $276.6M beats by $2.6M [3/6/2024 4:50 PM]	2.77	-0.48 (-14.88%)	2.73	-0.53 (-16.26%)	1.42 - 13.67	4,812,791	4,100,000	101,300
Emergent Biosolutions Non-GAAP EPS of -$0.77 misses by $0.45, revenue of $276.6M beats by $2.6M [3/6/2024 4:50 PM] Benchmark upgrades Emergent BioSolutions to Buy [3/7/2024 11:36 AM]
11-12-2023	PM		EBS	Emergent Biosolutions	125.00	-1.44	-0.12	0.00		2.12	-0.37 (-14.86%)	0.0	0.0 (0.00%)	1.81 - 16.66	1,413,470	1,440,000	0

09-11-2023	PM		EBS	Emergent Biosolutions, Inc.	121.75	N/A	0.05	-1.27	Emergent Biosolutions reports Q3 results; updates FY23 guidance [11/9/2023 3:41 AM]	2.15	-0.06 (-2.83%)	2.21	0.0 (0.00%)	1.92 - 17.39	1,065,599	1,290,000	713
Emergent Biosolutions reports Q3 results; updates FY23 guidance [11/9/2023 3:41 AM]
08-08-2023	AH		EBS	Emergent Biosolutions, Inc.	368.77	-1.06	-0.98	-0.86	Emergent Biosolutions Non-GAAP EPS of -$1.06 misses by $0.43, revenue of $337.9M beats by $121.15M [8/8/2023 4:37 PM]	5.91	-1.29 (-17.99%)	7.15	-0.05 (-0.69%)	5.53 - 30.94	4,869,929	1,630,000	6,529
Emergent BioSolutions to cut 400 jobs, streamline operations [8/8/2023 8:05 AM] Emergent Biosolutions Non-GAAP EPS of -$1.06 misses by $0.43, revenue of $337.9M beats by $121.15M [8/8/2023 4:37 PM]
09-05-2023	AH	4:15 PM ET (May 9)	EBS	Emergent Biosolutions, Inc.	451.57	-3.17	-1.67	0.18	Emergent Biosolutions GAAP EPS of -$3.65, revenue of $165M [5/9/2023 4:21 PM]	10.72	1.03 (10.57%)	8.89	-0.81 (-8.35%)	7.74 - 40.45	2,493,005	1,190,000	17,890
Emergent Biosolutions GAAP EPS of -$3.65, revenue of $165M [5/9/2023 4:21 PM]
27-02-2023	AH	4:15 PM ET (Feb 27)	EBS	Emergent Biosolutions, Inc.	697.44	-0.31	0.31	4.50	Emergent Biosolutions Q4 results mixed, co guides FY 2023 revenue in-line [2/27/2023 4:48 PM]	12.39	-1.61 (-11.46%)	13.54	-0.46 (-3.29%)	10.61 - 45.14	2,415,126	1,540,000	9,542
Emergent Biosolutions Q4 results mixed, co guides FY 2023 revenue in-line [2/27/2023 4:48 PM] Emergent BioSolutions off 4% on Q4 2022 bottom line miss [2/27/2023 5:34 PM]
08-11-2022	AH	4:05 PM ET (Nov 8)	EBS	Emergent Biosolutions, Inc.	973.80	-1.27	-0.05	-0.36	Emergent Biosolutions Non-GAAP EPS of -$1.27 misses by $1.14, revenue of $240M misses by $26.35M; cuts FY22 outlook [11/8/2022 4:24 PM]	12.79	-6.93 (-35.15%)	17.00	-2.73 (-13.84%)	12.00 - 52.28	3,510,166	590,000	20,072
Emergent Biosolutions Non-GAAP EPS of -$1.27 misses by $1.14, revenue of $240M misses by $26.35M; cuts FY22 outlook [11/8/2022 4:24 PM] Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance [11/9/2022 12:47 PM] AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates [Nov-07-22 06:45PM] Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards? [Nov-07-22 01:39PM] AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards? [Nov-07-22 10:06AM]
01-08-2022	AH	4:05 PM ET (Aug 1)	EBS	Emergent Biosolutions, Inc.	1,570	-0.86	0.63	0.33	Emergent Biosolutions Non-GAAP EPS of -$0.86 misses by $1.26, revenue of $242.7M misses by $25.66M [8/1/2022 4:17 PM]	30.21	-4.02 (-11.74%)	33.94	-0.29 (-0.85%)	26.85 - 66.78	1,411,973	560,000	1,994
Emergent Biosolutions Non-GAAP EPS of -$0.86 misses by $1.26, revenue of $242.7M misses by $25.66M [8/1/2022 4:17 PM] Emergent BioSolutions misses on top and bottom lines as it swings to quarterly loss [8/1/2022 7:23 PM] Emergent BioSolutions Reports Financial Results for Second Quarter 2022 [Aug-01-22 04:05PM]
28-04-2022	AH	4:05 PM ET (Apr 28)	EBS	Emergent Biosolutions, Inc.	1,870	0.18	0.23	1.53	Emergent Biosolutions Non-GAAP EPS of $0.18 beats by $0.11, revenue of $307.5M beats by $24.96M [4/28/2022 4:11 PM]	32.26	-4.36 (-11.90%)	33.75	-2.86 (-7.81%)	29.88 - 68.03	1,146,795	530,000	5,847
Emergent Biosolutions Non-GAAP EPS of $0.18 beats by $0.11, revenue of $307.5M beats by $24.96M [4/28/2022 4:11 PM] Emergent, contract manufacturer for J&J vaccines, falls on guidance suspension [4/28/2022 6:03 PM] Emergent BioSolutions dips on lowered price target at Cowen amid lowering Narcan revenue guidance [4/29/2022 1:51 PM] Emergent BioSolutions Reports Financial Results For First Quarter 2022 [Apr-28-22 04:05PM] Emergent Biosolutions (EBS) Q1 Earnings Lag Estimates [Apr-28-22 05:25PM] Why Emergent BioSolutions Stock Is Sinking Today [Apr-29-22 12:45PM] Emergent BioSolutions (EBS) Q1 2022 Earnings Call Transcript [Apr-29-22 06:30PM] Emergent BioSolutions Suspends CDMO Guidance As It Awaits Clarity On COVID-19 Vaccine Requirements [Apr-29-22 03:05PM] Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates [Apr-29-22 02:25PM]
24-02-2022	AH	4:05 PM ET (Feb 24)	EBS	Emergent Biosolutions, Inc.	2,270	4.50	3.88	3.67	Emergent Biosolutions Non-GAAP EPS of $4.50 beats by $0.08, revenue of $723.2M beats by $46.28M [2/24/2022 4:14 PM]	40.89	-1.45 (-3.42%)	42.34	0.0 (0.00%)	29.88 - 102.88	274,463	530,000	9,823
Emergent Biosolutions Non-GAAP EPS of $4.50 beats by $0.08, revenue of $723.2M beats by $46.28M [2/24/2022 4:14 PM] Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More [Feb-23-22 11:44AM] Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021 [Feb-24-22 04:05PM] Emergent BioSolutions (EBS) Q4 2021 Earnings Call Transcript [Feb-24-22 11:00PM] Why Emergent BioSciences Stock Is Slipping Today [Feb-25-22 11:58AM] Emergent BioSolutions to begin 'facility improvements' in Baltimore as J&J evaluates Covid vaccine demand [Feb-25-22 12:38PM] Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut [Feb-25-22 11:05AM] Emergent BioSolutions Stock Fell Today -- Is It a Buy? [Feb-25-22 04:31PM]
04-11-2021	AH	4:05 PM ET (Nov 4)	EBS	Emergent Biosolutions, Inc.	2,680	-0.36	2.03	2.19	Emergent Biosolutions EPS misses by $2.64, misses on revenue [11/4/2021 4:20 PM]	33.76	-18.85 (-35.83%)	40.05	-12.56 (-23.87%)	29.88 - 127.20	6,869,394	390,000	26,624
Emergent Biosolutions EPS misses by $2.64, misses on revenue [11/4/2021 4:20 PM] Emergent shares fall 15% after U.S. government ends vaccine contract early [11/4/2021 11:44 PM] Emergent Biosolutions granted FDA clearance for two more COVID-19 vaccine batches [11/5/2021 4:38 PM] Emergent BioSolutions Reports Financial Results For Third Quarter 2021 [Nov-04-21 04:05PM] Emergent BioSolutions, feds terminate long-running pandemic preparedness contract [Nov-04-21 05:28PM] Emergent BioSolutions inc (EBS) Q3 2021 Earnings Call Transcript [Nov-05-21 12:02AM] Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates [Nov-04-21 08:56PM] U.S. cancels multimillion dollar deal with Emergent BioSolutions, which produced contaminated J&J vaccines: report [Nov-05-21 05:48AM] Coronavirus tally: Global cases of COVID-19 top 248.7 million and U.S. cancels Emergent BioSolutions vaccine deal [Nov-05-21 06:26AM] Emergent BioSolutions Stock Plunges After Key Government Contract Terminated [Nov-05-21 06:41AM] Emergent slumps as U.S. terminates COVID-19 vaccine manufacturing deal [Nov-05-21 07:31AM] Emergent Biosolutions shares tumble on news it will lose COVID vaccine production contract with govt' [Nov-05-21 07:49AM] Emergent (EBS) Q3 Earnings Miss, Contract Revenue View Down [Nov-05-21 10:20AM] Why Emergent Biosolutions Stock Is Crashing Today [Nov-05-21 12:07PM] Emergent Tanks as U.S. Ends Contract, Vaccine Maker Cuts Outlook [Nov-05-21 08:06AM] U.S. authorizes more batches of J&J COVID-19 vaccine made at Emergent [Nov-05-21 04:38PM] See Why Emergent BioSolutions Stock Plunged 37% On Friday? [Nov-05-21 04:24PM]
29-07-2021	AH	4:05 PM ET (Jul 29)	EBS	Emergent Biosolutions, Inc.	3,360	0.33	1.81	1.98	Emergent Biosolutions EPS misses by $1.23, misses on revenue [7/29/2021 4:17 PM]	65.97	0.75 (1.15%)	62.00	-3.22 (-4.94%)	55.07 - 137.61	715,321	490,000	3,297
Emergent to restart COVID-19 vaccine production at Baltimore Plant [7/29/2021 6:46 AM] Emergent Biosolutions EPS misses by $1.23, misses on revenue [7/29/2021 4:17 PM] Emergent cites inquiries from U.S. authorities regarding its COVID-19 vaccine manufacturing [7/30/2021 12:55 PM] UPDATE 1-Emergent to resume J&J COVID-19 vaccine production at Baltimore plant [Jul-29-21 12:25AM] REFILE-J&J contractor plans to resume COVID-19 vaccine production at Baltimore plant - WSJ [Jul-28-21 11:24PM] REFILE-UPDATE 1-Emergent to resume J&J COVID-19 vaccine production at Baltimore plant [Jul-29-21 12:25AM] UPDATE 2-Emergent to resume J&J COVID-19 vaccine production at Baltimore plant [Jul-29-21 12:25AM] Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility [Jul-29-21 07:25AM] UPDATE 3-Emergent to resume J&J COVID-19 vaccine production at Baltimore plant [Jul-29-21 12:25AM] Sandy Hook families offered a settlement, J&J vaccine production resumes in Baltimore, AstraZeneca loses money on vaccine [Jul-29-21 11:01AM] Sandy Hook families offered $33 million, J&J vaccine production to resume in Baltimore, AstraZeneca loses money on vaccine [Jul-29-21 11:01AM] Emergent BioSolutions Stock Higher As COVID-19 Vaccine Production To Resume At Baltimore Plant [Jul-29-21 10:16AM] Emergent BioSolutions Reports Financial Results For Second Quarter 2021 [Jul-29-21 04:05PM] REFILE-UPDATE 3-Emergent to resume J&J COVID-19 vaccine production at Baltimore plant [Jul-29-21 12:25AM] UPDATE 4-Emergent to resume J&J COVID-19 vaccine production at Baltimore plant [Jul-29-21 06:30PM] Emergent Biosolutions (EBS) Lags Q2 Earnings and Revenue Estimates [Jul-29-21 07:25PM] Emergent BioSolutions inc (EBS) Q2 2021 Earnings Call Transcript [Jul-30-21 05:02AM] U.S. authorities probing Emergent BioSolutions over COVID-19 vaccine issues -filing [Jul-30-21 10:18AM] REFILE-U.S. authorities probing Emergent BioSolutions over COVID-19 vaccine issues -filing [Jul-30-21 10:04AM] UPDATE 1-U.S. authorities probing Emergent BioSolutions over COVID-19 vaccine issues- filing [Jul-30-21 10:42AM] U.S. authorities probing Emergent BioSolutions over COVID-19 vaccine issues - filing [Jul-30-21 10:18AM] Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit [Jul-30-21 09:54AM] UPDATE 2-US authorities probing Emergent BioSolutions over COVID-19 vaccine issues - filing [Jul-30-21 10:42AM] US authorities probing Emergent BioSolutions over COVID-19 vaccine issues - filing [Jul-30-21 10:18AM] EBS Long Term Investor Alert: Did You Acquire (EBS) Before April 24, 2020? - Contact Johnson Fistel Regarding Investigation [Jul-30-21 06:51PM]
29-04-2021	AH	4:05 PM ET (Apr 29)	EBS	Emergent Biosolutions, Inc.	3,430	1.53	0.97	0.01	Emergent Biosolutions EPS beats by $0.36, misses on revenue [4/29/2021 4:35 PM]	60.84	-2.31 (-3.66%)	61.50	-1.65 (-2.61%)	60.70 - 137.61	835,432	1,140,000	2,851
Emergent awaiting FDA OK to release 60M J&J vaccine doses - Bloomberg [4/29/2021 3:06 PM] Emergent Biosolutions EPS beats by $0.36, misses on revenue [4/29/2021 4:35 PM] CDC allocating J&J vaccine again, but still at low numbers [4/30/2021 12:46 PM] Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Emergent BioSolutions, and Verus International and Encourages Investors to Contact the Firm [Apr-28-21 09:00PM] SHAREHOLDER ALERT: MPLN KDMN EBS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines [Apr-28-21 05:20PM] Safirstein Metcalf LLP Announces That A Class Action Has Been Filed Against Emergent BioSolutions Inc. - EBS [Apr-28-21 04:00PM] SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS [Apr-28-21 03:08PM] HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact Its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEOs Insider Sales [Apr-28-21 02:25PM] EBS Stock: Berger Montague Investigates Potential Securities Fraud Claims Against Emergent BioSolutions Inc. (EBS); Lead Plaintiff Deadline is June 18, 2021 [Apr-28-21 02:14PM] EBS INVESTOR ALERT: Shareholder Class Action Lawsuit Filed [Apr-28-21 01:00PM] EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc. [Apr-28-21 12:45PM] INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Apr-28-21 11:02AM] EBS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Emergent BioSolutions Inc. Investors of Class Action and Encourages Investors to Contact the Firm [Apr-28-21 11:00AM] Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS) [Apr-28-21 11:00AM] Class Action Reminder: Labaton Sucharow LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (NYSE: EBS) [Apr-28-21 10:55AM] The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OTRK, LDOS and EBS [Apr-28-21 06:30AM] SHAREHOLDER ALERT: CLAIMSFILER REMINDS EBS, GOEV, RMO INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits [Apr-28-21 10:50PM] EBS EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of Emergent BioSolutions Inc. [Apr-28-21 09:55PM] CLASS ACTION UPDATE for SOS, FGEN and EBS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [Apr-29-21 06:30AM] EMERGENT SHAREHOLDERS: June 18, 2021 Filing Deadline in Class Action Contact Lieff Cabraser [Apr-29-21 09:01AM] The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLU, ATNX and EBS [Apr-29-21 10:25AM] EBS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Emergent BioSolutions Inc. Investors of Class Action and Encourages Investors to Contact the Firm [Apr-29-21 11:00AM] Emergent BioSolutions Inc. Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Deadline in Securities Fraud Class Action Lawsuit [Apr-29-21 11:11AM] INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Apr-29-21 11:35AM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PLUG, RIDE and EBS [Apr-29-21 12:30PM] INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Apr-29-21 01:15PM] Emergent BioSolutions Reports Financial Results for First Quarter 2021 [Apr-29-21 04:05PM] SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS [Apr-29-21 04:13PM] UPDATE 1-Emergent BioSolutions posts first-quarter profit on vaccine funding [Apr-29-21 04:55PM] Emergent BioSolutions posts first-quarter profit on vaccine funding [Apr-29-21 04:19PM] HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Fraud Class Action Filed, Application Deadline Established [Apr-29-21 05:03PM] Emergent Biosolutions (EBS) Q1 Earnings Top Estimates [Apr-29-21 05:45PM] UPDATE 2-Emergent hopes to answer U.S. FDA on Baltimore plant within days [Apr-29-21 04:55PM] Emergent hopes to answer U.S. FDA on Baltimore plant within days [Apr-29-21 04:19PM] EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent BioSolutions Inc. - EBS [Apr-29-21 07:14PM] SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Apr-30-21 12:50AM] ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - EBS [Apr-29-21 11:02PM] Emergent BioSolutions Inc (EBS) Q1 2021 Earnings Call Transcript [Apr-30-21 05:31AM] The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PLUG, EBON and EBS [Apr-30-21 06:30AM] EMERGENT INVESTORS: June 18, 2021 Filing Deadline in Class Action Contact Lieff Cabraser [Apr-30-21 09:00AM] New Strong Sell Stocks for April 30th [Apr-30-21 09:19AM] CLASS ACTION UPDATE for RIDE, FGEN and EBS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [Apr-30-21 10:05AM] Class Action Reminder: Labaton Sucharow LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (NYSE:EBS) [Apr-30-21 10:45AM] Emergent (EBS) Beats on Q1 Earnings, Cuts Contract Revenue View [Apr-30-21 10:06AM] DEADLINE ALERT for FUV, EBS, and ACAD: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders [Apr-30-21 11:00AM] EBS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Emergent BioSolutions Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm [Apr-30-21 11:00AM] SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Apr-30-21 11:40AM] Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS) [Apr-30-21 12:30PM] LAWSUITS FILED AGAINST FGEN, CAN and EBS - Jakubowitz Law Pursues Shareholders Claims [Apr-30-21 12:45PM] Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS) [Apr-30-21 02:03PM] Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days [Apr-30-21 11:14AM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of VLDR, REGI and EBS [Apr-30-21 02:30PM] ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline EBS [Apr-30-21 07:36PM] HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Class Action Filed, Application Deadline Approaching [Apr-30-21 07:00PM] Emergent BioSolutions Inc. -- Moody's affirms Emergent's Ba2 CFR; revises outlook to negative [Apr-30-21 05:55PM] Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg [Apr-30-21 02:35PM] Canada to not distribute JNJ COVID-19 vaccines until quality checks complete [Apr-30-21 08:01PM] UPDATE 1-Canada receives J&J's COVID-19 vaccine from plant where FDA halted production [Apr-30-21 08:20PM]
18-02-2021	AH	4:05 PM ET (Feb 18)	EBS	Emergent Biosolutions, Inc.	6,630	3.67	2.72	1.57	Emergent Biosolutions EPS beats by $0.26, beats on revenue [2/18/2021 4:28 PM]	102.94	-14.12 (-12.07%)	111.27	-5.79 (-4.95%)	46.37 - 137.61	1,980,724	440,707	4,959
Emergent Biosolutions EPS beats by $0.26, beats on revenue [2/18/2021 4:28 PM] Emergent Bio cut to neutral at Chardan on valuation [2/19/2021 3:25 PM] Looking Into Emergent BioSolutions's Return On Capital Employed [Feb-19-21 10:57AM] Emergent BioSolutions Inc (EBS) Q4 2020 Earnings Call Transcript [Feb-19-21 04:01AM] UPDATE 3-Vaccine manufacturing deals power Emergent BioSolutions profit beat [Feb-18-21 04:25PM] Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020 [Feb-18-21 04:05PM] Emergent BioSolutions, Inc. to Host Earnings Call [Feb-18-21 03:15PM]
05-11-2020	AH	4:25 PM ET (Nov 5)	EBS	Emergent Biosolutions, Inc.	4,910	2.19	2.05	1.21	Emergent Biosolutions EPS beats by $0.04, misses on revenue, revised FY20 guidance [11/5/2020 5:40 PM]	92.04	-4.96 (-5.11%)	93.35	-3.65 (-3.76%)	46.37 - 137.61	685,634	484,972	4,178

30-07-2020	AH	4:10 PM ET (Jul 30)	EBS	Emergent Biosolutions, Inc.	4,850	1.98	0.53	0.12	Emergent Biosolutions beats on revenue [7/30/2020 4:39 PM]	110.21	13.19 (13.60%)	104.03	7.01 (7.23%)	39.11 - 114.13	1,053,110	1,945,492	4,523